Kelly P A, Cannom D S, Garan H, Mirabal G S, Harthorne J W, Hurvitz R J, Vlahakes G J, Jacobs M L, Ilvento J P, Buckley M J
Cardiac Unit, Massachusetts General Hospital, Boston 02114.
J Am Coll Cardiol. 1988 Jun;11(6):1278-86. doi: 10.1016/0735-1097(88)90292-6.
Ninety-four patients underwent surgery for automatic implantable cardioverter-defibrillator implantation. Ninety patients were discharged from the hospital with the device and were followed up for a mean period of 17 +/- 10 months. Forty-six patients experienced at least one discharge of the device under circumstances consistent with a malignant ventricular arrhythmia. One sudden death occurred. Complications included perioperative death (3 patients), post-operative ventricular tachycardia (12 patients) and atrial fibrillation (8 patients), perioperative myocardial infarction (1 patient) and device discharges for sinus tachycardia and supraventricular arrhythmias (17 patients). Six and 12 month survival rates by life table analysis were 98.7 and 95.4%, respectively. Thus, the automatic implantable cardioverter-defibrillator is a highly effective and relatively low risk treatment modality for patients with refractory life-threatening ventricular arrhythmias.
94例患者接受了植入式自动心脏复律除颤器植入手术。90例患者出院时携带该装置，平均随访17±10个月。46例患者在符合恶性室性心律失常的情况下至少发生过一次装置放电。发生1例猝死。并发症包括围手术期死亡（3例患者）、术后室性心动过速（12例患者）和心房颤动（8例患者）、围手术期心肌梗死（1例患者）以及因窦性心动过速和室上性心律失常导致的装置放电（17例患者）。通过生命表分析得出的6个月和12个月生存率分别为98.7%和95.4%。因此，植入式自动心脏复律除颤器对于难治性危及生命的室性心律失常患者是一种高效且风险相对较低的治疗方式。
